Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonists

Area of Science:

• Pulmonology
• Pediatric Allergy and Immunology
• Pharmacology

Background:

• Asthma is a chronic inflammatory airway disease, with increasing prevalence and mortality in the US.
• Current asthma treatments have limitations, necessitating safer and more effective anti-inflammatory options, especially for pediatric populations.
• Leukotrienes are key lipid mediators implicated in asthma pathogenesis and symptomology.

Purpose of the Study:

• To evaluate the efficacy and tolerability of antileukotriene agents in managing asthma.
• To explore the potential of these drugs in addressing the limitations of existing asthma therapies.
• To assess the suitability of antileukotriene drugs for pediatric asthma patients.

Main Methods:

• Clinical trials were conducted to assess the impact of antileukotriene drugs on asthma.
• Data on pulmonary function, symptom reduction, and use of concomitant asthma medications were collected.
• Patient compliance and tolerability of orally bioavailable antileukotriene agents were evaluated.

Main Results:

• Antileukotriene drugs, including zafirlukast, montelukast, and zileuton, demonstrated improvements in pulmonary function in adult asthma patients.
• These agents effectively decreased asthma symptoms and reduced the need for other asthma medications.
• Orally administered antileukotriene agents were generally well-tolerated, suggesting potential for enhanced patient compliance.

Conclusions:

• Antileukotriene therapy represents a promising approach for managing asthma, particularly in children and young adults.
• Montelukast and zafirlukast are approved for pediatric asthma, with zafirlukast pending approval, highlighting their established safety and efficacy.
• These drugs offer a well-tolerated, orally available option to target the inflammatory pathways in asthma.